Site-Selective IgG Acetylation via Peptide Mediator
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for antibody functionalization, such as chemical modification of IgG, face challenges in achieving precise control over reaction sites, leading to heterogeneous populations of antibody-drug conjugates that complicate clinical use, and existing methods often result in bulky stubs or lack single-residue resolution.
Innovation Solution
The use of a novel Fc-III derived peptide with a glutamine derivative containing a phenyl azidoacetate motif for site-selective acetylation of Lys248 in the IgG Fc region, enabling bioorthogonal reactive groups for further derivatization and the construction of immunoliposomes and bispecific antibody complexes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemical modification methods are used to functionalize antibodies, then the therapeutic index can be enhanced, but precise control over reaction sites cannot be achieved, leading to heterogeneous populations of antibody-drug conjugates
Solution Approach 1:
The patent employs Protein G as an intermediary mediator that specifically binds to the Fc region of IgG antibodies, positioning a catalytic system near specific lysine residues (particularly Lys248 in the Fc region). This proximity-induced catalysis enables site-selective acetylation without affecting other lysine residues throughout the antibody structure, thus achieving homogeneous antibody-drug conjugates with controlled reaction sites while maintaining enhanced therapeutic index.
2Ease of manufacture
If existing chemical functionalization methods are applied to antibodies, then reactive groups can be activated, but bulky stubs are left on the protein or single-residue resolution is not achieved
Solution Approach 1:
The invention implements local quality by creating a localized catalytic environment through Protein G binding, which concentrates the acetylation reaction specifically at Lys248 of the Fc region. The proximity-induced catalytic system ensures that only the nearby lysine residue undergoes acetylation, achieving single-residue resolution (modifying one specific lysine out of many in the antibody) while maintaining ease of manufacture through a streamlined biochemical process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for precise and stable modification of IgG, enabling targeted therapy by inducing effector-cell mediated cytotoxicity at nanomolar concentrations and improving the therapeutic index of antibodies.
Implementation Method 1
In certain embodiments, only the heavy chain of the antibody is acetylated. In certain embodiments, a single lysine residue of the antibody is acetylated. In preferred embodiments, the lysine reside is Lys248 of IgG Fc.
Data Source
AI summary
The subject invention pertains to methods of acetylation of the Fc region of immunoglobulins, particularly Lys248 of the heavy chain of human Immunoglobulin G (IgG) using a novel Fc-III derived peptide. The acetylation reaction with the phenolic ester with an azide or alkyne enables site-selective functionalization of Lys248 with a bioorthogonal reactive group for further derivatization. Further methods are provided to synthesize an antibody-lipid conjugate that allows for the construction of an immunoliposome that can target cells expressing oncogenes, including HER2+ cells, and a bispecific antibody complex (bsAbC) linking two distinct antibodies. The bsAbC can induce an effector-cell mediated cytotoxicity at nanomolar concentrations.